创胜医药
TRANSCENTA

Transcenta Holding Limited
創勝集團醫藥有限公司
(registered by way of continuation in the Cayman Islands with limited liability)
(Stock Code: 6628)

VOLUNTARY ANNOUNCEMENT

TRANSCENTA REPORTS RECEIPT OF HICB OUT-LICENSING MILESTONE PAYMENT AND STEADY CDMO BUSINESS GROWTH

This announcement is made by Transcenta Holding Limited (the "**Company**" or "**Transcenta**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update. Capitalized terms used herein but not otherwise defined shall have the same meaning ascribed thereto in the prospectus of the Company dated September 14, 2021.

The board of directors of the Company (the "**Board**") is pleased to announce the receipt of a milestone payment of RMB 7 million from its HiCB (highly intensified continuous bioprocessing) platform out-licensing, alongside significant progress in its CDMO business.

Following the strategic collaboration and non-exclusive licensing agreement with EirGenix Inc. ("**EirGenix**") (TWSE: 6589) executed in late 2025, and receipt of the associated upfront payment, the two companies have achieved significant technical milestones, triggering the first milestone payment. To date, Transcenta has successfully completed key deliverables. The collaboration is steadily advancing toward implementing the HiCB technology for GMP production at EirGenix's facility.

To drive further commercialization of the HiCB platform, Transcenta recently appointed its former Chief Technology Officer (CTO), Dr. Christopher Hwang, as Head of Global Partnerships for the HiCB platform, where he will lead the global technology out-licensing strategy and oversee platform implementation. Under his leadership, Transcenta will continue to scale this non-exclusive licensing model, which allows the Company to retain full technology ownership while generating revenue from licensing fees, customized CHO culture medium optimization service, and ongoing medium supply, with proceeds reinvested into platform upgrading and the core R&D pipeline.

Concurrently, Transcenta is making steady progress in its CDMO business. The Company has recently signed new service contracts of GMP Drug Substance (DS) production for complex biologics using its HiCB processes for bioprocessing technology, as well as GMP Drug Product (DP) manufacturing for siRNA projects. Transcenta is also currently negotiating contracts for additional high-potential projects, including integrated IND development projects, siRNA GMP DP production, developability assessments, and material generation for global clients.

As the HiCB out-licensing program gains traction and the CDMO business continues to expand, Transcenta remains well-positioned to drive sustainable growth and deliver long-term value to its partners and shareholders.

Forward Looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By Order of the Board
Transcenta Holding Limited
Xueming Qian
Executive Director, Chairman and Chief Executive Officer

Hong Kong, May 26, 2026

As at the date of this announcement, the Board comprises Dr. Xueming Qian as executive Director, chairman and chief executive officer, Dr. Li Xu as non-executive Director and Mr. Jiasong Tang, Mr. Zhihua Zhang, Dr. Kumar Srinivasan and Ms. Helen Wei Chen as independent non-executive Directors.